Increasing evidence suggests nicotinic receptors regulate developmental events in the nervous system. We used [
nicotinic receptors, however, at both early and late embryonic stages are those having high affinity for ␣-bungarotoxin rather than epibatidine. Most contain ␣7 subunits, whereas about half contain ␣8 subunits as well. The sharpest developmental increase between embryonic days 8 and 17/18 occurs with receptors containing ␣5 subunits, whereas receptors containing ␣3 or ␤4 subunits undergo no specific increase. The three major receptor species (containing ␣4 and ␤2 but not ␣5 subunits; ␣7 subunits; or ␣7 and ␣8 subunits) each increase Ϸ3-fold during the same period. The results indicate greater receptor complexity than appreciated previously; they provide information about the rules governing subunit assembly in neuronal nicotinic receptors and draw attention to the role of ␣5 subunits in late development.
AChRs in the vertebrate nervous system are ligand-gated ion channels that depolarize neurons by permitting cations to flow across the plasma membrane. Like their counterparts in vertebrate skeletal muscle, the receptors are thought to be pentameric transmembrane proteins encoded by one or more members of a multigene family (Karlin and Akabas, 1996) . It is clear that neuronal AChRs can participate in a variety of functions. Presynaptically, the receptors can modulate neurotransmitter release, whereas postsynaptically, they can generate synaptic currents from both synaptic and perisynaptic locations (Role and Berg, 1996; Zhang et al., 1996; Wonnacott, 1997) . Some classes of AChRs have a high relative permeability to calcium and can influence calcium-dependent events in neurons, including activation of second messenger cascades.
Neuronal AChRs may play important developmental roles as well. The receptors are expressed early during embryogenesis, as is the enzyme responsible for synthesis of ACh (Zoli et al., 1995; Role and Berg, 1996) . AChRs can be found on the tips of growing neurites in cell culture and, when activated, can influence the pattern of neurite growth. Presynaptic AChRs also can enhance neurotransmitter release at newly formed neuromuscular synapses in culture (Fu and Liu, 1996) , and they may contribute to the early stages of synaptogenesis.
It is not clear which AChR subtypes are likely to be most important during development, or, in fact, how many AChR subtypes exist. Nine genes encoding neuronal AChR subunits (␣2-7; ␤2-4) have been isolated from both chick and rat (Role and Berg, 1996) . In addition, ␣8 has been isolated uniquely from chick, and ␣9 has been isolated uniquely from rat. Two major AChR subtypes have been identified in brain from both species: one is a receptor with ␣4 and ␤2 subunits that binds nicotine with high affinity, and the other is a receptor with ␣7 subunits that binds ␣-Bgt with high affinity (Lindstrom, 1996) . Receptor analyses with subunit-specific mAbs also have identified other AChR subunit combinations in brain (Flores et al., 1996; Lindstrom, 1996; Forsayeth and Kobrin, 1997) .
Recently, the alkaloid epibatidine emerged as a broadspectrum cholinergic ligand for neuronal AChRs. [ 3 H]Epibatidine seems to bind with high affinity to all AChR species examined to date, except for some that bind ␣-Bgt (Gerzanich et al., 1995; Houghtling et al., 1995; Wang et al., 1996) . As a result, [ 3 H]epibatidine, together with 125 I-␣-Bgt and subunitspecific mAbs, offers a means of identifying and quantifying additional AChR subtypes in brain. In the current report, we used this strategy to address four questions: Do the major AChR species identified in brain contain other gene products as well? Do individual AChR genes often contribute subunits to different AChR subtypes in the central versus peripheral nervous system? Can new AChR subtypes be detected? Do the relative amounts of individual AChR subtypes change substantially during development? Answers to these questions should provide information about the rules governing subunit assembly in neuronal AChRs and may help identify the receptor species most important at early developmental stages.
Experimental Procedures
mAbs. All subunit-specific mAbs used in the current study have been characterized and described previously (see references in Vernallis et al., 1993; Conroy and Berg, 1995) . Regarding specificities with chicken neuronal AChR gene products, mAbs 270, 289, 308, 313, and B4-1 both immunoprecipitate and immunoblot selectively the ␤2, ␣4, ␣8, ␣3, and ␤4 gene products, respectively, whereas mAbs 318 and 319 do the same with the ␣7 gene product. mAb 268 selectively immunoblots (but does not immunoprecipitate) the ␣5 gene product, whereas mAb 35 immunoprecipitates and immunoblots the ␣5 gene product (it was raised against electric organ AChRs and recognizes the ␣1 subunit therein). Experiments with transfected cells indicate that mAb 35 also immunoprecipitates receptors with ␣3 subunits but does not recognize the ␣4, ␣7, ␣8, ␤2, or ␤4 gene products (Conroy et al., 1992; W. Conroy and D. Berg, unpublished observations) . Unless otherwise indicated, the mAbs were diluted from concentrated stocks of hybridoma culture supernatants, or mouse ascites fluid (B4-1 only) for use or were purified using Protein G-Sepharose-4-Fast-Flow (Pharmacia, Piscataway, NJ) or size exclusion chromatography (mAb 289). Purified mAbs 35, 270, 289, 313, and B4-1 and normal IgG were coupled individually to Actigel (Sterogene Bioseparations, Arcadia, CA) at 2-4 mg/ml according to the manufacturer's specifications.
Binding assays. Whole brains were dissected from embryonic day (E) 8-18 chicks and stored frozen at Ϫ70°until use. Triton X-100 (Pierce Chemical, Rockford, IL) extracts of the brains were prepared as described previously (Conroy et al., 1992) using two to four volumes of 2% (w/v) Triton X-100 extraction buffer/g of tissue. For filter binding assays, 2-4 nM [ 3 H]epibatidine or 5-10 nM 125 I-␣-Bgt was incubated with 25 l of brain extract in a total volume of 0.1 ml for 2 hr at room temperature. After the incubation, 4 ml of wash buffer (10 mM Tris, pH 7.5, containing 0.05% Triton X-100) was added, and the solution was filtered immediately through Whatman (Clifton, NJ) GF/B filters presoaked in 0.5% polyethyleneimine. The filters were washed two additional times with 4 ml of wash buffer and counted either by liquid scintillation counting in Ecolite (ICN, Costa Mesa, CA) for [ 3 H]epibatidine or by ␥-counting for 125 I-␣-Bgt. Nonspecific binding was determined by incubation in the presence of 200 M nicotine. Protein in the extracts was quantified by the BCA Protein Assay (Pierce) using bovine serum albumin as standard.
[ 3 H]Epibatidine binding sites associated with specific AChR subunits were quantified using a modification of a solid-phase immunoprecipitation assay and the mAbs 35 (␣3, ␣5), 270 (␤2), 289 (␣4), 313 (␣3), and B4-1 (␤4) to tether AChRs. Immulon 2 Removawells (Dynatech Laboratories, Chantilly, VA) were coated with mAb by first incubating the wells overnight at 4°on a shaker with affinity-purified rabbit anti-mouse antibodies (Jackson Immunoresearch, West Grove, PA) at a concentration of 20 g/ml in PBS (1ϫ ϭ 0.15 M sodium chloride and 0.01 M sodium phosphate, pH 7.4) containing 0.02% azide. The wells then were washed three times with PBS-TX and incubated on a shaker overnight at 4°with 50 l of anti-AChR mAb diluted in buffer. The wells were rinsed three times with PBS-TX and incubated overnight with the detergent extracts. The extracts were removed, and the wells were washed four times with PBS-TX. [ 3 H]epibatidine and were carried out for 4 hr at room temperature. Plots of competition curves were generated, and IC 50 values were determined by a nonlinear least-squares method using Prism (GraphPAD Software, San Diego, CA) assuming a single class of sites in each case. K D values for epibatidine were determined from saturation binding reactions in which the receptor concentration did not exceed 60 pM. Because ligand depletion may nevertheless have had some effect on the K D determinations (Kenakin, 1993) , the values are considered approximate (apparent K D values).
Immunodepletions. Extracts were depleted of AChR subtypes by incubation of extracts (0.2 ml) with 40 l of anti-AChR mAb coupled to Actigel beads. After an overnight incubation, the Actigel beads with bound material were removed by centrifugation. [ 3 H]Epibatidine binding sites then were quantified in the depleted extracts using the filter binding assay.
AChRs also were depleted by incubation of extracts in Immulon 2 Removawells (Dynatech Laboratories) coated with mAbs 270 or 289, as described above for the solid-phase immunoprecipitation assay, to remove AChRs containing ␤2 and ␣4 subunits, respectively. After recovery of the depleted extracts from the wells, they were used in a solid-phase assay with [ 3 H]epibatidine to quantify the remaining AChRs. Similarly, a combination of mAbs 318 and 319 was used to deplete AChRs with ␣7 subunits, and mAb 308 was used to deplete AChRs with ␣8 subunits.
125 I-␣-Bgt binding sites remaining in the depleted extracts then were quantified by the filter binding assay. In sequential depletion experiments, recovered extracts from one round of depletion were subjected to a second round of depletion in a new well containing either the same mAb as in the first round or an mAb to another subunit. In all depletion experiments, normal rat IgG was used in place of the anti-AChR mAbs as a negative control.
Immunoprecipitations and immunoblots. AChRs containing ␣4, ␤2, and ␣5 subunits were analyzed by monitoring the coprecipitation of ␣5 subunits with AChRs containing both ␣4 and ␤2 subunits. Similar analyses have been used to show the association of ␣3, ␣5, and ␤4 subunits in ganglia (Vernallis et al., 1993; Conroy and Berg, 1995) . E8 and E18 brain extracts containing equal amounts of protein (0.7 mg) were incubated on Immulon 2 Removawells (Dynatech Laboratories) coated with mAb 289, as described above for the solid-phase assay, to remove AChRs containing ␣4 subunits. Removawells coated with normal rat IgM served as the negative control. Extracts recovered from these wells then were incubated overnight with 20 l of mAb 270-Actigel to bind AChRs containing ␤2 subunits. The gel was washed three times with PBS-TX and 2 times with PBS-TX containing 1 M NaCl. Bound material was eluted with SDS-PAGE sample buffer, subjected to SDS-PAGE, electroblotted to nitrocellulose, and probed with mAbs 268 for ␣5 and 289 for ␣4 as described previously (Vernallis et al., 1993; Conroy and Berg, 1995 (Whiting et al., 1991) were kindly provided by Dr. Paul Whiting (Merk, Sharp, & Dohme Laboratories, Essex, England) . An ␣5 cDNA kindly provided by M. Ballivet (University of Geneva, Geneva) was modified to delete untranslated 3Ј and 5Ј sequences and to add the ␣3 leader sequence, which has an efficient Kozak consensus sequence for translation initiation. The modified ␣5 construct was subcloned into the RSV.An vector (obtained from D. Donahue, University of California, San Diego) under an RSV promoter.
Transfections were performed on HEK 293 cells obtained from J. Wahl (Salk Institute, La Jolla, CA) and grown in Eagle's minimum essential medium supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, and 50 units each of penicillin and streptamycin. The cells were plated at 3.4 ϫ 10 5 /35-mm culture dish and maintained at 37°in 95% air/5% CO 2 . After 24 hr, the cells were transfected using calcium phosphate-DNA precipitation in a BES buffer as described previously (Chen and Okayama, 1987) . Transfections usually contained 1 g of ␣4, 0.2 g of ␤2, and/or 0.5 g of ␣5 cDNA/dish; pBluescript SK Ϫ DNA (Stratagene, La Jolla, CA) was added as needed to adjust the total to 2 g in each case. The ratio of ␣4 to ␤2 cDNA was chosen to optimize the amount of After 18-24 hr of transfection, the cells were washed with fresh medium, incubated an additional 24 hr, and then harvested by scraping in 0.5 ml of solubilization buffer containing 50 mM sodium phosphate, pH 7.4, 1% Triton X-100, and the protease inhibitors iodoacetamide (0.4 mM), benzamidine (5 mM), phosphoramidon (5 g/ml), soybean trypsin inhibitor (10 g/ml), leupeptin (10 g/ml), pepstatin A (20 g/ml), EDTA (5 mM), EGTA (5 mM), aprotinin (2 g/ml), and phenylmethylsulfonyl fluoride (1 mM). Insoluble material was removed by centrifugation for 15 min in a microfuge at 4°. [ 3 H]Epibatidine binding sites were quantified using the solid-phase assay. Immunoblot analysis was used to confirm the expression of transfected genes.
Materials. White Leghorn embryonated chick eggs were obtained locally and maintained at 39°in a humidified incubator as described by Conroy et al. (1992) . mAb 35 was purified and radioiodinated as described by Smith et al. (1985) . ␣-Bgt was purchased from Biotoxins (St. Cloud, FL) and radioiodinated to a specific activity of 0.5-0.7 ϫ 10 18 cpm/mol using chloramine T. [ 3 H]Epibatidine (56.5 Ci/mmol) was a generous gift from DuPont-New England Nuclear (Boston, MA). Unlabeled epibatidine was purchased from Research Biochemicals (Natick, MA). mAbs 268, 270, 289, 308, 313, 318 , and 319 were generously supplied by Dr. Jon Lindstrom (University of Pennsylvania, Philadelphia, PA). All compounds were purchased from Sigma Chemical (St. Louis, MO) unless otherwise indicated. Dr. Paul Whiting (Merck, Sharp, & Dohme Laboratories) generously provided the chicken AChR ␣4 and ␤2 gene constructs, and Dr. Marc Ballivet (University of Geneva, Geneva, Switzerland) generously provided the chicken AChR ␣5 cDNA. Dr. Jeffrey Wahl (Salk Institute, La Jolla, CA) provided the HEK 293 cells, and Dr. Daniel Donoghue (University of California, San Diego) provided the RSV.An vector.
Results

Epibatidine-binding AChRs in brain.
Filter binding assays were used to measure the total number of epibatidine binding sites present in chick brain extracts. A mean value of 109 Ϯ 28 fmol/mg of protein (mean Ϯ standard error; three experiments) was obtained with 2 nM [ 3 H]epibatidine for extracts prepared from E17/18 chick brain. No additional sites were revealed by increasing the concentration of epibatidine (data not shown), which is consistent with previous studies showing that 2 nM epibatidine is sufficient to saturate epibatidine binding sites on neuronal AChRs (Gerzanich et al., 1995; Houghtling et al., 1995; Wang et al., 1996) . Immunodepletion with subunit-specific mAbs before conducting the filter assays provides a means of identifying AChR gene products making up the epibatidine-binding receptors. Anti-␣4 mAb 289 immunodepleted Ϸ75% of the epibatidine binding capacity of E17/18 brain extracts, whereas anti-␤2 mAb 270 immunodepleted Ϸ85% (Fig. 1A) . No significant depletion was caused by either anti-␣3 mAb 313 or 3 H]epibatidine binding and subunit-specific mAbs. A, Receptors containing ␣4 or ␤2 subunits. Detergent extracts of E17/18 chick brains were incubated with the indicated mAbs (depleting mAb with indicated specificity) to deplete AChRs. The depleted extracts then were assayed for [
3 H]epibatidine binding in filter binding assays. Normal rat IgG was used as a negative control for the immunodepletions. mAbs to either the ␣4 or ␤2 gene products depleted most of the [ anti-␤4 mAb B4-1. mAb 35, which recognizes the neuronal ␣3 and ␣5 gene products, immunodepleted Ϸ10% of the binding. The results are consistent with the major epibatidinebinding AChR species in E17/18-brain containing the ␣4 and ␤2 gene products. Few AChRs at this stage contain either the ␣3 or ␤4 gene products, but a portion are likely to contain the ␣5. This latter conclusion comes from the different amounts of immunodepletion achieved by mAbs 313 and 35.
A more sensitive method for identifying subpopulations of brain AChRs capable of binding epibatidine is to use a solidphase immunoprecipitation assay. In this case, a subunitspecific mAb is used to immunotether all receptors containing a given gene product, and then [ 3 H]epibatidine binding is used to quantify the number of receptors retained by the antibody. By this criterion, many epibatidine-binding receptors in E17/18 brain extracts seem to contain only the ␣4 and ␤2 gene products (␣4/␤2-AChRs; Fig. 1B) . The anti-␣4 mAb 289 immunoprecipitated 86 Ϯ 13% (three experiments), whereas the anti-␤2 mAb 270 immunoprecipitated 93 Ϯ 12% of the total [
3 H]epibatidine binding measured with the filter assay. mAb 289 is specific under these conditions; it does not, for example, retain in the two-site assay chick ciliary ganglion AChRs that contain the ␣3, ␤4, and ␣5 subunits coassembled (Vernallis et al., 1993) and bind epibatidine in E17/18 extracts (data not shown).
Only small numbers of binding sites were retained by either the anti-␣3 mAb 313 or the anti-␤4 mAb B4-1 in E17/18 brain extracts (Fig. 1B) . mAb 35, in contrast, immunotethered approximately one sixth of the total number of sites. Control experiments performed with E17/18 ciliary ganglion extracts demonstrated that mAb 35 is 2.0 Ϯ 0.1-fold (mean Ϯ standard error; three experiments) more efficient than mAb 313 in the two-site assay at capturing AChRs containing the appropriate subunit (summing two sequential immunoprecipitations for each mAb). Identical experiments performed on E17/18 brain extracts indicated that mAb 35 was able to capture 12.1 Ϯ 4.6-fold (three experiments) more receptors than mAb 35 (again summing two sequential passes with each mAb). The results are consistent with those in Fig. 1B and suggest that substantially more brain AChRs contain ␣5 subunits than ␣3 subunits. This, together with the other immunoprecipitation data, is consistent with most of the brain receptors recognized by mAb 35 being ␣4/␤2/␣5-AChRs.
Subunits coassembled with the ␣4 and ␤2 gene products. The ability of the ␣4 and ␤2 gene products to form receptors that bind nicotine with high affinity is well documented (Whiting et al., 1991; Lindstrom, 1996) . Less clear is the extent to which the two kinds of gene products are associated with other kinds of subunits in brain AChRs. This was tested by using a combination of immunodepletions and solid-phase assays. One mAb was used to immunodeplete all receptors containing a given gene product, whereas a second mAb was used to immunotether the remaining receptors containing a different gene product. The tethered receptors then were quantified with [
3 H]epibatidine binding in the solid-phase assay. By comparing the binding values obtained with and without the immunodepletion step, it was possible to assess the proportion of receptors containing both gene products.
When the anti-␣4 mAb 289 was used for immunodepletion, approximately three fourths of the epibatidine-binding receptors containing the ␤2 gene product were removed from the extract (Fig. 2A) . In addition, more than half of the receptors containing either the ␣3 or ␤4 gene products were removed. More than half of the receptors recognized by mAb 35 also were removed by the depletion with mAb 289. To test the efficiency of the immunodepletion step, the depleted extracts were tested for residual receptors containing the ␣4 gene product; approximately one fifth of the control value remained. Taking into account the immunodepletion efficiency determined in this manner, the results indicate that most of the brain AChRs containing the ␤2 gene product and more than half of the receptors containing the ␣3 or ␤4 gene products also contain the ␣4 gene product. The same is likely to be true of receptors containing the ␣5 gene product and Immunodepletion with the anti-␤2 mAb 270 removed Ͼ80% of the ␣4-and ␤2-containing receptors, corroborating the results obtained with mAb 289 (Fig. 2B) . Between one half and three fourths of the ␣3 and ␤4-containing receptors were removed, as was more than three fourths of the receptors recognized by mAb 35. More than three fourths of the ␤2-containing receptors also were removed by the immunodepletion, demonstrating the efficiency of the antibody. The results support previous findings indicating that a substantial portion of the ␣4 and ␤2 gene products are assembled into ␣4/␤2-AChRs with no other apparent subunits. The results also show, however, that some ␣4 and ␤2 subunits combine with additional kinds of subunits to make up a heterogeneous population of epibatidine-binding AChRs in the CNS.
Coassembly of ␣4, ␤2, and ␣5 subunits in transfected cells. The fact that mAb 35 immunoprecipitates many more epibatidine-binding sites from brain extracts than does the ␣3-specific mAb 313 suggests that the receptors contain ␣5 subunits instead of ␣3 subunits. These could represent ␣4/ ␤2/␣5-AChRs and constitute a significant fraction of all brain receptors containing the ␣4 and ␤2 gene products at the end of embryogenesis. Recently, the ␣5 gene product has been shown capable of assembling with ␣4 and ␤2 when coexpressed in Xenopus laevis oocytes (Ramirez-Latorre et al., 1996) . We examined this issue in cells that were not oocytes.
HEK 293 cells were transiently transfected with various combinations of the ␣4, ␤2, and ␣5 cDNAs. Two days later, cell extracts were prepared and examined in solid-phase assays for receptors that could bind [ 3 H]epibatidine and be immunotethered by anti-AChR mAbs. The ␣4 and ␤2 gene combination produced a large number of receptors tethered either by anti-␣4 mAb 289 or by anti-␤2 mAb 270, but none were recognized by mAb 35 (Fig. 3) . Inclusion of ␣5 cDNA in the transfection with ␣4 and ␤2 had little effect on the total number of epibatidine-binding receptors tethered by mAbs 289 or 270 but generated a significant number of receptors recognized by mAb 35. Transfection with ␣5 alone, ␣5 plus ␣4, or ␣5 plus ␤2 yielded no significant epibatidine binding retained by any of the mAbs. The results clearly indicate that the ␣5 gene product can combine with the ␣4 and ␤2 gene products to produce epibatidine-binding ␣4/␤2/␣5-AChRs.
Ligand binding properties of AChR subtypes. In X. laevis oocytes, heterologous expression of the chick AChR ␣4 and ␤2 genes with and without the ␣5 gene shows that ␣4/␤2/␣5-AChRs have a 100-fold higher EC 50 value for activation by ACh than that of ␣4/␤2-AChRs (20). In contrast, expression of the human ␣5 gene in oocytes with the ␣3 and ␤4 genes has no effect on the ACh dose-response curve, whereas expression of ␣5 with the ␣3 and ␤2 genes shifts the EC 50 value to smaller values (Wang et al., 1996) .
To examine the possible contribution of ␣5 subunits to the pharmacology of native AChRs containing the ␣4 and ␤2 gene product, we first used mAb 35 to isolate a population of receptors from brain extract that included those with ␣5 subunits. mAb 289 then was used on the same mAb 35-depleted extracts to isolate a receptor population containing ␣4 (and presumably ␤2) but not ␣5 subunits. Binding assays revealed no significant difference in the affinity of the two (Fig. 4) . A comparison of IC 50 values indicated at most a nominal 5-fold difference in affinity between putative ␣4/␤2/␣5-and ␣4/␤2-AChRs isolated from brain extract as described above (Table 1 ). The IC 50 values for ␣4/␤2/␣5-and ␣4/␤2-AChRs from transfected cells were essentially indistinguishable from their brain counterparts. The results are consistent with the inferred subunit composition of the brain AChR subtypes and indicate little effect of ␣5 subunits on ligand affinity in binding assays.
Changing populations of epibatidine-binding AChRs during development. The relative contributions of individual AChR gene products to epibatidine-binding AChR subtypes in brain were measured during development. The goal was to determine whether different species predominated at early versus late times. Solid-phase assays revealed three patterns. Of the epibatidine-binding AChRs, receptors containing either the ␣4 or the ␤2 gene product were the most abundant at all times examined and increased developmentally Ϸ3-fold between E8 and E17/18 (Fig. 5A) . This was over and above increases due to cell growth as reflected in the amount of total protein. Receptors containing either the ␣3 or ␤4 gene products were the least abundant at all times examined and showed no developmental increase between E8 and E17/18; the small increase in binding sites represented net growth because no change was apparent when the values were normalized for protein. Most striking was the change in the number of epibatidine-binding receptors recognized by mAb 35. These increased 7-fold between E8 and E17/18 when normalized for protein (Fig. 5B) . Because no developmental increase was observed in the number of receptors containing the ␣3 gene product over the same time period, much of the increase is likely to involve receptors with ␣5 subunits.
Immunoblot analysis provides a method for using the available mAbs to confirm the presence of individual gene products in AChRs and determine whether developmental increases in receptors recognized by mAb 35 correlates with increases in receptors containing ␣5 subunits. Brain AChRs were concentrated by immunoprecipitation, eluted, gel electrophoresed, and analyzed on blots probed with subunitspecific mAbs. All five AChR gene products inferred above to be present in brain AChRs were detected on the blots (Fig.  6A) . The relative amounts of ␣5 protein assembled with ␣4 and ␤2 protein at early and late developmental stages then was assessed by using the anti-␤2 mAb 270 to immunoprecipitate the receptors. The material was eluted, electropho- 
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at ASPET Journals on August 27, 2017 molpharm.aspetjournals.org resed, and analyzed on blots probed with mAb 289 to detect ␣4 protein and mAb 268 to detect ␣5 protein. Both ␣4 and ␣5 protein could be detected, and both increased substantially between E8 and E17/18 (Fig. 6B) . Immunodepletion with the anti-␣4 mAb 289 before immunoprecipitation with mAb 270 removed large amounts of the ␣4 and ␣5 proteins subsequently detected on the blots. The results confirm the conclusions that a portion of the native AChRs containing ␣4 and ␤2 subunits also contain ␣5 subunits and that the amount of this species increases developmentally. Interestingly, a portion of the ␣5 protein also seems to be associated with a different receptor species late in development because some of the ␣5 gene product associated with ␤2 (and immunoprecipitated by the anti-␤2 mAb 270) cannot be immunodepleted by the anti-␣4 mAb 289 (Fig. 6B) .
Developmental changes in the population of brain AChRs that bind ␣-Bgt. The total number of ␣-Bgt-binding AChRs detected in brain extracts using 125 I-␣-Bgt in the filter assay was substantially higher at all stages examined than was the total number of epibatidine-binding AChRs (Fig. 7A) . A developmental increase of Ϸ3-fold occurred in the number of ␣-Bgt-binding receptors between E8 and E17/18. Immunodepletion with the anti-␣7 mAbs 318/319 indicated that most of the ␣-Bgt-binding receptors at both early and late times in embryonic brain contain the ␣7 gene product, whereas approximately half also contain the ␣8 gene product (Fig. 7B) . Sequential immunoprecipitations were required to collect all of the receptors containing the ␣8 gene product, presumably because of the inefficiency of the antibody. A small fraction of the total ␣-Bgt-binding AChRs at both early and late times may contain gene products other than ␣7 and ␣8 gene because some ␣-Bgt-binding species remained in solution even after repeated immunoprecipitations. A similar fraction of ␣-Bgt-binding species remained in E17/18 ciliary ganglion extracts after sequential immunoprecipitations in the two-site assay with mAbs 318/319 (data not shown), and a portion of this has been attributed previously to an AChR 2, 4, 6 , and 8) immunodepletion with the anti-␣4 mAb 289 (depleting mAb) and then subjected to SDS-PAGE, electroblotted, and probed (probe mAb) with either the anti-␣4 mAb 289 (lanes 1-4) or the anti-␣5 mAb 268 (lanes 5-8) . Almost all of the ␣5 protein at E8 is coassembled with both ␣4 and ␤2 subunits, and the amount increases substantially by E17/18. Some of the ␣5 protein at the later developmental stage also is found in a species lacking ␣4 subunits. species lacking the ␣7 gene product (Pugh et al., 1995) . Much of the remainder, however, could represent receptor in which the relevant epitopes are blocked or degraded. No significant change was observed between E8 and E17/18 in the ratios of the ␣-Bgt-binding species in brain.
Discussion
Epibatidine and ␣-Bgt together as probes distinguish several major classes of AChRs in brain. Most abundant are receptors binding ␣-Bgt and containing either ␣7 or ␣7 plus ␣8 subunits. Together they make up at least three fourths of the total ␣-Bgt-binding species at all developmental stages examined and represent nearly two thirds of the total AChRs distinguished in the combined filter assays. The findings are consistent with earlier reports of abundant ␣-Bgt-binding AChRs containing ␣7 and ␣8 subunits in chick brain (Gotti et al., 1994a; Lindstrom, 1996) . The current study shows that only a small fraction of the total ␣-Bgt binding in brain at either early or late developmental times is a candidate for receptor species lacking both the ␣7 and ␣8 gene products. Gotti et al. (1994b) reported that approximately half of the ␣-Bgt-binding receptors in chick brain between E7 and E13 could not be immunoprecipitated by antisera against either ␣7 or ␣8 peptides. The reason for the discrepancy between the earlier results and those reported here is not clear but may be due to differences in the efficiency of receptor immunoprecipitation in the two studies.
The next most abundant species of brain AChRs is one that binds epibatidine and contains the ␣4 and ␤2 gene products. These constitute Ͼ80% of the total epibatidine-binding receptors at all developmental stages examined and represent Ϸ15% of the total brain AChRs detected in filter assays with epibatidine and ␣-Bgt. The same AChR subtype was identified previously as a major species capable of binding nicotine with high affinity in rat and chick brain (Lindstrom, 1996) .
Another AChR species distinguished here in brain is one that binds epibatidine and contains not only the ␣4 and ␤2 gene products but also gene products recognized by mAb 35. Previous studies in chick have shown that mAb 35 recognizes the ␣3 and ␣5 neuronal AChR gene products but not the ␣4, ␣7, ␣8, ␤2, or ␤4 gene products (Conroy et al., 1992; Vernallis et al., 1993; Lindstrom, 1996) . Because the anti-␣3 mAb 313 is unable to immunoprecipitate the vast majority of such receptors, they are unlikely to contain ␣3 subunits. Instead, sequential immunoprecipitations with other mAbs followed by immunoblot analysis with the anti-␣5 mAb 268 confirm that a portion of the AChRs in brain containing ␣4 and ␤2 subunits also contain ␣5 subunits and seem to be ␣4/␤2/␣5-AChRs.
Heterologous coexpression of ␣4, ␤2, and ␣5 constructs in both X. laevis oocytes (Ramirez-Latorre et al., 1996) and HEK 293 cells produces ␣4/␤2/␣5-AChRs. An electrophysiological comparison of ␣4/␤2-and ␣4/␤2/␣5-AChR in oocytes shows that the ␣5 subunit reduces receptor affinity for ACh as judged by dose-response curves (Ramirez-Latorre et al., 1996) . Binding studies on receptors from HEK 293 cells, however, reveal no difference between ␣4/␤2-and ␣4/␤2/␣5-AChRs in affinity for several nicotinic ligands. A likely reason for the different results is that the electrophysiological analysis measured ligand affinity of nondesensitized receptors, whereas the equilibrium binding studies used for the current report almost certainly measured ligand affinity of desensitized receptors. An alternative possibility is that oocytes and HEK 293 cells influence receptor pharmacology differently through the kinds of post-translational modifications they provide. A similar argument has been advanced to account for differences in the single-channel events seen for AChRs produced by oocytes versus neurons (Sivilotti et al., 1997) . Consistent with current results, previous researchers (Lindstrom, 1996) have found no difference in the binding affinities of nicotine, cytisine, or epibatidine for chick brain AChRs immunoprecipitated by either mAb 35 or anti-␣4 mAbs. The results underscore the need for caution in using pharmacology alone to draw conclusions about subunit composition, but they do not conflict with the conclusion based on immunoprecipitations and immunoblot analysis showing that the ␣5 gene product coassembles with ␣4 and ␤2 in brain.
In situ hybridization analyses demonstrate that ␣4 and ␤2 transcripts are widely expressed in both rat and chick brain (Wada et al., 1989; Morris et al., 1990) . Although the distribution of ␣5 mRNA has not been examined in chick, in situ hybridization studies in rat brain show extensive overlap between regions expressing ␣5 transcripts and those expressing ␣4 and ␤2 (Wada et al., 1990) . Overlap also is found in both rat and chick between brain regions expressing ␣3 and those expressing ␣4 and ␤2 (Wada et al., 1989; Morris et al., 1990; Lobron et al., 1995) . The same is true for ␤4 expression in rat brain (Dineley-Miller et al., 1992) .
Three remaining neuronal AChR genes in chick, ␣2, ␣6, and ␤3, were not included in the current study because subunit-specific antibodies were not available. Least relevant is ␤3 because in situ hybridization analysis indicates that expression of the gene is largely confined to the retina and trigeminal ganglion in chick (Hernandez et al., 1995) . Both the ␣2 and ␣6 genes are expressed in chick brain (Wada et al., 1989; Daubas et al., 1990; Gerzanich et al., 1997) and may contribute subunits to receptors currently thought to be either ␣4/␤2-AChRs or ␣4/␤2/␣5-AChRs. Neither ␣2 nor ␣6 is likely to define a large class of entirely separate brain AChRs, however, because most epibatidine-binding receptors can be immunoprecipitated by both anti-␣4 and anti-␤2 mAbs. The ␣2 and ␣6 gene products could, in principle, account for some of the mAb 35 binding to brain AChRs. Preliminary results opposing this for the ␣2 gene product come from immunoprecipitations with mAb 321, which was raised against an ␣2-specific peptide sequence (R. Schoepfer, W. Conroy, and J. Lindstrom, unpublished observations); mAb 321 immunoprecipitates only 1-2% of the total epibatidine-binding receptors from E17/18 chick brain extracts (W. Conroy and D. Berg, unpublished observations) . The ␣6 gene product has yet to be tested for mAb 35 binding but is not a likely candidate because it lacks a critical moiety in the domain recognized by the antibody (Saedi et al., 1990; Gerzanich et al., 1997) . Nevertheless, the subunit heterogeneity of AChRs that bind mAb 35 and contain ␣4 and ␤2 gene products could be even greater than shown here.
Previous studies indicated that neuronal AChRs can contain more than one kind of ␣-type subunit, as well as more than one kind of ␤-type subunit (Conroy et al., 1992; Vernallis et al., 1993; Conroy and Berg, 1995; Lindstrom, 1996; Ramirez-Latorre et al., 1996; Wang et al., 1996; Forsayeth and Kobrin, 1997 ). An individual AChR gene product also can enter into different subunit associations depending on the partners available. The current findings extend this pattern, showing that AChR gene products common in the peripheral nervous system also are expressed in the central nervous system but largely assemble with different partners in the two cases. Thus, the ␣5 gene product is assembled with ␣3, ␤2, and ␤4 in autonomic neurons but usually not with ␣4 (Listerud et al., 1991; Vernallis et al., 1993; Mandelzys et al., 1994; Conroy and Berg, 1995; Flores et al., 1996) , whereas in brain, ␣5 subunits are assembled in considerable measure with ␣4 and ␤2. Similarly, the ␣3 and ␤4 gene products are assembled with ␣5 and to some extent ␤2 in autonomic neurons but usually not with ␣4 (Listerud et al., 1991; Vernallis et al., 1993; Mandelzys et al., 1994; Conroy and Berg, 1995; Flores et al., 1996) , whereas in brain ␣3 and ␤4 are assembled mostly with ␣4 and ␤2.
Changing AChR patterns during brain development suggest that receptors containing the ␣3 and ␤4 gene products are likely to be most important at early times and less so at later stages because their levels undergo no developmental increase beyond that present at E8. This view is consistent with in situ hybridization studies in rat showing that ␣3 and ␤4 mRNA appear early in development and then virtually disappear from the brain and spinal cord at later times (Zoli et al., 1995) . Transcripts for ␣7 and for ␣4 and ␤2 in rat brain undergo more sustained increases throughout development (Broide et al., 1995; Ostermann et al., 1995; Zoli et al., 1995; del Toro et al., 1997) , which is consistent with the sustained developmental increases in AChRs containing the gene products reported here. An interesting exception is the case of ␤2 gene expression in chick optic tectum, which is transient and dependent on innervation from the eye (Matter et al., 1990) .
The largest developmental increase observed in the current study was that of AChRs recognized by mAb 35. They undergo a 7-fold increase between E8 and E17/18 over and above that expected from net growth and represent approximately one sixth of all epibatidine-binding receptors at the end of embryogenesis. Immunoblot analysis confirmed a developmental increase in ␣5 protein associated with ␣4 and ␤2 subunits in such receptors. Some of the increase in epibatidine-binding AChRs recognized by mAb 35 also may represent the appearance of receptors containing ␣5 subunits coassembled with different AChR gene products, however, because not all of the receptors could be immunoprecipitated by anti-␣4 mAbs. In fact, AChRs that bind mAb 35 constitute approximately one half of the receptors capable of high affinity nicotine binding in adult chicken brain and can be immunoprecipitated by the anti-␤2 mAb 270 but not by the anti-␣4 mAb 285 (Lindstrom, 1996) . The subunit composition of this species includes components of 49 and 58 kDa (Whiting and Lindstrom, 1986) , with the former being in the size range expected for both the ␣5 and ␤2 proteins (Conroy et al., 1992) .
Differences in subunit composition are likely to influence many aspects of receptor function. Among these are the rates of receptor activation and desensitization, agonist sensitivity, calcium permeability, second messenger regulation, and possibly location on the cell surface. Considered broadly, the fact that a given AChR gene product is assembled with different subunit partners suggests the receptors perform different physiological functions but share a need for the specific features conferred by individual subunits. Identification of unique features contributed by individual subunits is a challenge for subsequent studies.
